Novacap, a global player in pharmaceutical synthesis and specialty products, announces the signature of an agreement to acquire PCI Synthesis, a US company specializing in the development and contract manufacturing of pharmaceutical ingredients (CDMO ).
Located in the heart of the Boston area's pharmaceutical and biotechnology hub, PCI Synthesis offers its customers a wide range of services including research and process development, clinical development and commercial production of active pharmaceutical ingredients and other specialty intermediates.
The company operates an R&D center in Devens (Massachusetts) and a manufacturing site in Newburyport (Massachusetts), and generates sales of $32 million. PCI has grown significantly in recent years, positioning itself as a strategic partner to the U.S. pharmaceutical and biotech industries, thanks to a wide range of services and technologies, strong responsiveness and recognized project management skills.
The combination of the two companies will give PCI Synthesis the resources it needs to pursue its development, and will strengthen Novacap's pharmaceutical synthesis capabilities, which now include 12 cGMP sites, 2 main R&D centers and a comprehensive range of services and technologies to support customers throughout the clinical and commercial phases.
"The acquisition of PCI Synthesis is perfectly in line with the Group's strategy of strengthening our offering to the pharmaceutical industry and accelerating our development in the United States. We have been impressed by PCI's success, its pipeline of projects and its growth prospects. Our two companies have complementary CDMO activities and share common values such as entrepreneurship, operational excellence and customer focus. We look forward to working with the PCI teams", said Pierre Luzeau, CEO of PCI. said Pierre Luzeau, President of Novacap Group.
Completion of this acquisition remains subject to approval by the competition authorities.
